Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
Escalating health care costs have made it imperative to evaluate the resources required to diagnose and treat major illnesses in Canadians.
For Canadian men, lung cancer is not only the most common malignancy, but also the major cancer killer.
As of 1994, lung cancer is expected to overtake breast cancer as the leading cause of cancer deaths in women.
This paper presents a detailed description of the methodology used to determine the direct health care costs associated with'standard'diagnostic and therapeutic approaches for lung cancer in Canada in 1988.
Clinical algorithms were developed for each stage of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).
The algorithms were designed to take the form of decision trees for each clinical stage of lung cancer.
The proportion of patients assigned to each branch was based upon questionnaire responses obtained from thoracic surgeons and radiation oncologists when presented with clinical scenarios, and information from provincial cancer registries.
Direct care costs were derived primarily from one provincial fee schedule (Ontario), and costing information obtained during the conduct of several Canadian clinical trials in lung cancer.
Direct costs for diagnosis and initial treatment of NSCLC (excluding relapse and terminal care costs) ranged from $17 889 for the surgery/post-operative radiotherapy arm of stages I and II to $6 333 for the supportive care arm (stage IV).
Mots-clés Pascal : Carcinome petite cellule, Bronchopulmonaire, Carcinome non petite cellule, Diagnostic, Traitement, Coût, Economie santé, Algorithme, Canada, Amérique du Nord, Amérique, Homme, Appareil respiratoire pathologie, Poumon pathologie, Bronche pathologie, Tumeur maligne
Mots-clés Pascal anglais : Oat cell carcinoma, Bronchopulmonary, Non small cell carcinoma, Diagnosis, Treatment, Costs, Health economy, Algorithm, Canada, North America, America, Human, Respiratory disease, Lung disease, Bronchus disease, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0010916
Code Inist : 002B11A. Création : 01/03/1996.